Clinical Trial Update: Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating adjuvant targeted therapy for patients with resected high-risk EGFR-mutant stage IB-IIA non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Tongji University | Conditions: NSCLC, EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN